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Abstract
Background: Neurocritical illness is a growing healthcare problem with profound socioeconomic effects. We assessed
differences in healthcare costs and long-term outcome for different forms of neurocritical illnesses treated in the intensive
care unit (ICU).
Methods: We used the prospective Finnish Intensive Care Consortium database to identify all adult patients treated for
traumatic brain injury (TBI), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH) and acute ischemic stroke
(AIS) at university hospital ICUs in Finland during 2003–2013. Outcome variables were one-year mortality and permanent
disability. Total healthcare costs included the index university hospital costs, rehabilitation hospital costs and social security
costs up to one year. All costs were converted to euros based on the 2013 currency rate.
Results: In total 7044 patients were included (44% with TBI, 13% with ICH, 27% with SAH, 16% with AIS). In comparison
to TBI, ICH was associated with the highest risk of death and permanent disability (OR 2.6, 95% CI 2.1–3.2 and OR 1.7, 95%
CI 1.4–2.1), followed by AIS (OR 1.9, 95% CI 1.5–2.3 and OR 1.5, 95% CI 1.3–1.8) and SAH (OR 1.8, 95% CI 1.5–2.1 and OR 0.
8, 95% CI 0.6–0.9), after adjusting for severity of illness. SAH was associated with the highest mean total costs (€51,906)
followed by ICH (€47,661), TBI (€43,916) and AIS (€39,222). Cost per independent survivor was lower for TBI (€58,497) and
SAH (€96,369) compared to AIS (€104,374) and ICH (€178,071).
Conclusion: Neurocritical illnesses are costly and resource-demanding diseases associated with poor outcomes. Intensive
care of patients with TBI or SAH more commonly result in independent survivors and is associated with lower total
treatments costs compared to ICH and AIS.
Keywords: Neurocritical care; neurointensive care; costs, Outcome; cost-effectiveness, Traumatic brain injury, Intracerebral
hemorrhage, Acute ischemic stroke, Subarachnoid hemorrhage, Finland
Background
Neurocritical illnesses, including traumatic brain injury
(TBI), intracerebral hemorrhage (ICH), subarachnoid
hemorrhage (SAH) and acute ischemic stroke (AIS), are
major killers and impose a growing socioeconomic burden
around the world [1–4]. The most severe illnesses or in-
juries are treated at specialized intensive care units (ICU).
Intensive care is, however, very resource-demanding, com-
prising for example almost 0.7% of the national gross
domestic product in the USA [5]. Furthermore, the need
costs of intensive care beds appears to continue to rise
[5–8]. Due to limited healthcare budgets clinicians and
hospital administrators are interested in measuring and
evaluating intensive care cost-effectiveness. Patients
with neurocritical illnesses constitute approximately
20–25% of severely ill patients requiring intensive care
(unpublished data from the Finnish Intensive Care
Consortium). Still, cost-analysis studies of neurocritical
illnesses are lacking [9].
Finland offers a unique setting to comprehensively
assess healthcare costs. Finland has a public tax-funded
healthcare system, allowing every citizen to be equally
treated at the right level of care at every step (including
acute care and rehabilitation), independent of for example
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socioeconomic factors and insurance status. In regard to
neurocritical disease, all specialized neurointensive care
has been centralized to five university hospitals for several
decades. Thus, all the most severe and resource-
demanding cases are treated at the university hospital
level, enabling comprehensive cost-analysis studies. Fur-
thermore, the Social Insurance Institution (Kela) in
Finland covers all Finnish citizens regardless of personal
insurance status.
The aim of this study is to describe differences in total
one-year healthcare costs and one-year mortality and
treatment cost-effectiveness following ICU admission
after neurocritical disease (TBI, ICH, SAH and AIS). Es-
pecially, we aimed to study treatment cost-effectiveness
of independent survivors.
Methods
Study design and study population
Finland has a publicly funded three-tier healthcare sys-
tem, where five university hospitals provide the highest
level of care, including specialized neurointensive care.
We used the Finnish Intensive Care Consortium (FICC)
database to include all adult patients (age ≥ 18 years)
treated for TBI, ICH, SAH or AIS in the five university
hospitals in Finland from 2003 to 2013. The FICC data-
base is a nationwide prospective data-collecting database
including all ICU-treated patients from the majority of
all ICUs in Finland [10].
We defined TBI, ICH, SAH and AIS according to the
Acute Physiology and Chronic Health Evaluation III
(APACHE III) diagnosis and International Classification of
Diseases and Related Health Problems, 10th Revision
(ICD-10) diagnosis. We confirmed the TBI and ICH diag-
noses by reviewing the patients’ computerized tomography
(CT) head scans obtained on admission. ICH and SAH
diagnoses do not include those due to trauma (these are
coded as TBI). We excluded patients with missing baseline
data (non-emergency admission, missing Glasgow Coma
Scale (GCS) score, missing pre-admission functional sta-
tus, missing cost data, see Fig. 1).
Extracted variables
We extracted the following variables from the FICC data-
base: age, GCS score, pre-admission functional status,
significant chronic comorbidity, mechanical ventilation,
length of ICU stay, length of hospital stay, Therapeutic
Intervention Scoring System 76 (TISS-76 [11]), APACHE
II [12], Simplified Acute Physiological Score II (SAPS II
[13]) and first-day Sequential Organ Failure Assessment
(SOFA [14]) score. In FICC, the GCS score is defined as
the worst measured GCS score during the first ICU day or
the last reliable GCS was used for intubated and/or se-
dated patients according to the SAPS II definition [13].
Pre-admission functional status is a modified version of
the World Health Organization/Eastern Cooperative On-
cology (WHO/ECOG) classification used in the FICC
[15]. Significant chronic comorbidity is defined according
to the APACHE II and SAPS II definitions [12, 13]. The
TISS-76 score includes 76 items measuring nursing staff
workload and the intensity of given treatments. It was
originally developed as a tool to quantify the workload
and treatment intensity required by ICU-treated patients,
but has since also been used as a dynamic measure of
patient prognosis [16].
Definition of outcome variables
We used one-year mortality and a surrogate marker for
permanent disability as outcome variables. We obtained
data on date of death through the Finnish population
register (available for all patients) and the archive of
death certificates. We defined patients permanently
disabled if they were granted a permanent disability
allowance or disability pension by the Social Insurance
Institution (Kela) by 30 September 2016. The criteria for
Kela to grant permanent disability allowance or disability
pension is being unable to independently carry out daily
activities (e.g. self-hygiene, basic housekeeping, take care
of things outside the home) or to be unable to return to
work, for a minimum of one consecutive year. The Kela
criteria for granting permanent disability allowances did
not change during the study period [17]. We also report
hospital mortality rates.
Definition of cost variables
The total healthcare cost variable consists of three param-
eters: university hospital costs, rehabilitation hospital costs
and social security costs up to one year after the index
admission [17]. We obtained university hospital costs
directly from the hospitals’ billing departments. University
hospital costs includes expenses from the whole treatment
period, including e.g. personnel costs, surgery, ICU stay,
laboratory costs, radiological costs, and costs of ward stay.
Fig. 1 Flow chart. Abbreviations: TBI, traumatic brain injury; ICH,
intracerebral hemorrhage; SAH, subarachnoid hemorrhage; AIS, acute
ischemic stroke; FICC, Finnish Intensive Care Consortium; GCS,
Glasgow Coma Scale
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We calculated rehabilitation hospital costs by multiplying
the length of rehabilitation stay by the average price of
one ward day in the designated level-of-care unit, accord-
ing to a report from the Finnish National Institute for
Health and Welfare [18]. We obtained social security costs
directly from Kela. Social security costs include for
example disability allowances, sickness allowances, private
physician and physiotherapist expenses, prescription drug
expenses and medical travel costs. In Finland, Kela is a
Finnish government agency funded by tax money, insur-
ance payments, and municipalities that provide all social
security payments in Finland. Thus, social security pay-
ments are not dependent upon, for example, personal
insurance. We adjusted all costs according to the Con-
sumer Price Index (CPI) in Finland to euros based on the
currency rate in 2013:
CPI adjusted cost ¼ Cost  CPI in 2013
Admission year CPI
Statistics
We used SPSS Statistics 24.0 for mac OS (IBM Corp,
Armonk, NY, USA) and Stata Statistical Software for
mac OS (StataCorp LP, College Station, TX, USA) for
the statistical analyses. We compared categorical vari-
ables using the chi-squared (χ2) test with the Bonferroni
correction. We tested continuous data for skewness and
as all variables were highly skewed they are reported as
medians with interquartile ranges (IQR), unless other
specified (such as cost data). We compared non-para-
metric continuous variables between groups using a
non-parametric test. We present cost data as means with
95% confidence intervals (CI) and compared means
between groups using the t test.
To compare costs adjusted for severity of illness be-
tween the different diagnostic groups we created a sever-
ity of illness model using multivariate logistic regression
analysis, with one-year mortality and permanent disabil-
ity (for one-year survivors) as the dependent variable,
separately for the diagnostic groups to weight the pre-
dictors according to the diagnostic group. The severity
of illness model included variables that were significantly
(p ≤ 0.05) associated with one-year mortality in univari-
ate analysis. These were the same for all diagnoses: age,
GCS score, chronic comorbidity, pre-admission func-
tional status and SAPS II score (excluding age, GCS
score, and chronic comorbidity). SAPS II was chosen
over APACHE II in accordance with findings from our
previous studies [19, 20]. The predictive ability of the
severity of illness model was assessed by the area under
the receiver operating curve (AUC).
We then used multivariate linear regression analysis
(regress in Stata), adjusting for variables in the severity
of illness model to assess differences in costs between
the diagnostic groups. We also used the same model in
a multilevel mixed-effect logistic regression model
(melogit in Stata) to assess differences in risk of one-year
mortality and permanent disability between the diagnos-
tic groups. Diagnosis (TBI, ICH, SAH, AIS) was modeled
as a random effect and considered as the random part of
the intercept, as the effect of the included variables may
be different in respective diagnostic groups.
To evaluate cost-effectiveness, we calculated the effective
cost per survivor (ECPS) and effective cost per independent
survivor (ECPIS), which is defined as the cost for all
patients divided by the number of one-year survivors or
independent one-year survivors [21]. As a sensitivity
analysis we divided patients into four risk bands according
to probability (0–25%, 26–50%, 51–75%, 76–100%) of
one-year mortality within the diagnostic group. We con-
ducted the study according to the Strengthening the report-
ing of observational studies in epidemiology (STROBE)
guidelines (Additional file 1).
Results
The final study population included 7044 patients (Fig. 1).
Of these, 3097 had TBI (43%); 949 had ICH (14%); 1875
had SAH (27%) and 1123 had AIS (16%). Patient baseline
characteristics are shown in Table 1. Patients with AIS or
ICH were older those with than TBI or SAH, respectively.
The GCS score was lower among patients with TBI or
ICH compared to SAH or AIS. Patients were predomin-
antly female only in the group of patients with SAH. Pa-
tients with SAH had the best pre-admission functional
status. There were no major differences in significant co-
morbidities between the diagnostic groups. Patients with
SAH had the longest ICU and hospital length of stay.
Mean daily treatment intensity measured using the
TISS-76 was similar in patients with TBI, ICH or SAH but
lower among patients with AIS. Total treatment intensity
was notably higher in patients with SAH compared to the
other groups. Patients with ICH had the highest SAPS II
and APACHE II scores followed by patients with TBI,
SAH or AIS.
Severity of illness models
The AUC for the severity of illness model, for one-year
mortality prediction, including all patients, was 0.86 (95%
CI 0.85–0.87), indicating good discrimination. The AUC
was 0.85 (95% CI 0.84–0.87) for patients with TBI, for
ICH the AUC was 0.85 (95% CI 0.82–0.87), for SAH the
AUC was 0.89 (95% CI 0.87–0.90) and for AIS the AUC
was 0.88 (95% CI 0.85–0.90). The AUC for the severity of
illness model, for permanent disability prediction (for
one-year survivors), including all patients, was 0.71 (95%
CI 0.70–0.73), indicating satisfactory discrimination. The
AUC was 0.73 (95% CI 0.70–0.75) for patients with TBI,
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for ICH the AUC was 0.67 (95% CI 0.62–0.71), for SAH
the AUC was 0.72 (95% CI 0.69–0.75) and for AIS the
AUC was 0.68 (95% CI 0.64–0.72).
The overall probability of one-year mortality, reflecting
severity of illness, decreased during the study period
(Fig. 2). This decrease was most profound in patients
with AIS or ICH (Additional file 2). With time the rela-
tive proportion of patients in the two lowest risk bands
(0–25%, 26–50% vs. 51–75%, 76–100%) became greater
in all diagnostic groups but especially in the ICH and
AIS groups (Additional file 3).
Patient outcome
Patient outcome is shown in Table 2. Hospital mortality
was highest among patients with ICH (28%), followed by
SAH (18%), AIS (16%) and TBI (13%). One-year mortal-
ity was highest among patients with ICH (44%) followed
by AIS (29%), SAH (27%) and TBI (25%). In a multilevel
mixed-effect logistic regression model, using TBI as the
reference group, ICH was associated with the highest
risk of one-year mortality (OR 2.61, 95% CI 2.15–3.16)
followed by AIS (OR 1.90, 95% CI 1.55–2.33) and SAH
(OR 1.79, 95% CI 1.51–2.11).
Permanent disability in one-year survivors was highest
among patients with ICH (51%), followed by AIS (47%),
TBI (37%) and SAH (26%). In the multilevel mixed-effect
logistic regression model, using TBI as the reference
group, ICH was associated with the highest risk of per-
manent disability (OR 1.75, 95% CI 1.42–2.14) followed by
AIS (OR 1.53, 95% CI 1.27–1.85). In contrast, SAH was
associated with a lower risk of permanent disability com-
pared to TBI (OR for SAH in comparison to TBI was
0.75, 95% CI 0.64–0.88).
Costs and cost-effectiveness
Overall mean cost per patient was €45,799 (95% CI
€44,597–€47,001) out of which 45% constituted university
hospital costs (mean €20,493, 95% CI 19,945–21,040), 39%
Table 1 Patient baseline characteristics
Variables TBI (N = 3097) ICH (N = 949) SAH (N = 1875) AIS (N = 1123) P value
Age (median, IQR) 56 (41–67) 61 (52–69) 56 (47–65) 68 (59–76) < 0.001
18–40 years 750 (24%) 71 (7%) 193 (10%) 42 (4%) < 0.001
41–64 years 1455 (47%) 509 (54%) 1201 (64%) 420 (37%)
≥ 65 years 892 (29%) 369 (39%) 481 (26%) 661 (59%)
GCS score, median (IQR) 9 (5–14) 8 (4–13) 12 (5–15) 12 (8–15) < 0.001
3–8 1465 (47%) 497 (52%) 704 (38%) 313 (28%) < 0.001
9–12 598 (20%) 172 (18%) 262 (14%) 253 (22%)
13–15 1034 (33%) 280 (30%) 909 (48%) 557 (50%)
Female 711 (23%) 332 (35%) 1065 (57%) 443 (39%) < 0.001
Pre-admission functional statusa < 0.001
Fit for work or equal 1896 (61%) 613 (65%) 1473 (79%) 717 (64%)
Unfit for work, but independent in self-care 967 (31%) 252 (27%) 332 (18%) 275 (24%)
Partially dependent in self-care 180 (6%) 61 (6%) 47 (2%) 110 (10%)
Totally dependent in self-care 54 (2%) 23 (2%) 23 (1%) 21 (2%)
Significant chronic comorbidityb 267 (9%) 108 (11%) 154 (8%) 138 (12%) < 0.001
Mechanical ventilation 2070 (67%) 640 (67%) 1241 (66%) 427 (38%) < 0.001
LOS ICU, days (median, IQR) 2 (1–4) 2 (1–3) 3 (1–6) 1 (1–2) < 0.001
LOS hospital, days (median, IQR) 6 (3–11) 6 (3–12) 10 (6–16) 6 (4–11) < 0.001
TISS-76 daily averagec (median, IQR) 27 (21–33) 26 (20–31) 28 (24–34) 19 (14–27) < 0.001
TISS-76 totalc (median, IQR) 69 (42–154) 63 (39–126) 102 (63–230) 44 (27–74) < 0.001
APACHE II score (median, IQR) 19 (13–25) 20 (13–26) 17 (11–24) 14 (9–22) < 0.001
SAPS II score (median, IQR) 35 (24–50) 40 (25–55) 29 (20–48) 29 (23–45) < 0.001
SOFA scored (median, IQR) 6 (3–8) 6 (3–9) 6 (3–9) 3 (1–7) < 0.001
Abbreviations: AIS, acute ischemic stroke; APACHE, Acute Physiology and Chronic Health Evaluation; GCS; Glasgow Coma Scale; ICH, intracerebral hemorrhage; LOS,
length of stay; ICU, Intensive Care Unit; SAH, subarachnoid hemorrhage; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; TBI,
traumatic brain injury; TISS-76, Therapeutic Intervention Scoring System 76
aA modified World Health Organization/Eastern Cooperative Oncology Group classification system implemented by the Finnish Intensive Care Consortium
bAny chronic comorbidity according to APACHE II or to SAPS II
cMissing for 6 patients
dMissing for 9 patients
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rehabilitation hospital costs (mean €18,064, 95% CI
€17,245–18,883) and 16% social security costs (mean
€7242, 95% CI €6992–€7492).
Differences in costs between the diagnostic groups are
shown in Table 2. University hospital costs were notably
higher for patients with SAH compared to the other diag-
nostic groups (€25,717 vs. €15,819–€19,568). Rehabilitation
costs were similar between the groups, being slightly higher
for patients with TBI or ICH compared to SAH or AIS
(€18,435 and €21,361 compared to €16,673 and €16,579).
Social security costs were highest for patients with SAH
and lowest for patients with TBI (€9516 vs. €5913).
Change in the sum of costs for all patients is shown in
Fig. 3. In 2003, the sum of costs for all patients was
€18.6 million. In 2013, this sum had risen to €32.7
million or on average by 7% per year. Still, the mean cost
per patient decreased on average by 2% from 2003 to
2013 (Fig. 3). Changes in the sum of costs for the
different diagnostic groups is shown in Additional file 4.
The sum of costs increased notably in all groups with
the most marked relative increase in patients with AIS.
Additional file 5 shows changes in mean cost per patient
during the study period. On average, the mean cost per
patient decreased in patients with TBI or ICH, remained
Fig. 2 Changes in mean probability of one-year mortality (with 95% confidence intervals), reflecting patient severity of illness. Probabilities are
calculated by logistic regression analysis, adjusting for age, Glasgow Coma Scale score, significant comorbidity, pre-admission functional status
and the modified Simplified Acute Physiology Score II. The y-axis scale extends from 0 to 0.4, where 0 indicates that the probability is 0% and 0.4
that the probability is 40%. Severity of illness decreased markedly from 2007 to 2009, where after it remained largely the same
Table 2 Mean costs and unadjusted outcomes by diagnosis
Outcome TBI (N = 3097) ICH (N = 949) SAH (N = 1875) AIS (N = 1123) P value
Hospital mortality 12.5% (11.3–13.6) 27.6% (24.8–30.5) 18.3% (16.5–20.0) 16.4% (14.2–18.6) < 0.001
One-year mortality 24.7% (23.2–26.2) 43.8% (40.7–47.0) 27.1% (25.1–29.1) 28.7% (26.0–31.3) < 0.001
Permanent disabilitya 36.7% (34.8–38.7) 51.0% (46.8–55.3) 26.0% (23.7–38.4) 46.9% (43.5–50.4) < 0.001
Mean costs
University hospital costs €19,568 (18,707–20,429) €18,721 (17,125–20,316) €25,717 (24,722–26,713) €15,819 (14,665–16,972) < 0.001
Percentage of total costs 45% 39% 50% 40%
Rehabilitation hospital €18,435 (17,164–19,706) €21,361 (19,055–23,667) €16,673 (15,112–18,234) €16,579 (14,720–18,437) < 0.001
Percentage of total costs 42% 45% 32% 42%
Social security costs €5913 (5608–6217) €7579 (6791–8367) €9516 (8975–10,057) €6824 (6158–7491) < 0.001
Percentage of total costs 13% 16% 18% 17%
Total costs €43,916 (42,096–45,735) €47,661 (44,198–51,123) €51,906 (49,544–54,268) €39,222 (36,541–41,903) < 0.001
Outcome data presented as percentages with 95% confidence intervals (CI). Cost data presented as means with 95% CIs
Abbreviations: AIS, acute ischemic stroke; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage; TBI, traumatic brain injury
Costs shown in euros (€) at the 2013 rate
aPermanent disability for one-year survivors
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unchanged in patients with AIS and increased in pa-
tients with SAH.
In the linear regression model, adjusting for the severity
of illness model using TBI as the reference population,
SAH was associated with the highest costs (€7761, 95% CI
€4813–€10,709, p < 0.001), followed by ICH (€4044, 95%
CI €305–€7782, p = 0.034). On the contrary, AIS was asso-
ciated with a lower total cost compared to TBI (− 4861
euros, 95% CI − 8365 to − 1357 euros, p = 0.007).
In regard to cost-effectiveness, AIS had the lowest
ECPS, followed by TBI, SAH and ICH. However, the
ECPIS for TBI and SAH was lower than for AIS and
ICH (Fig. 4). In the sensitivity analysis, TBI and SAH
had the lowest ECPIS in all risk bands (Additional file 6).
In the most severely ill patients in risk band 4, TBI and
AIS had the lowest ECPS, while TBI and SAH had the
lowest ECPIS. ICH was associated with the lowest
cost-effectiveness in all risk bands.
Discussion
Principal findings
In this comprehensive cost-analysis study, we found that
the burden of ICU-treated TBI, ICH, SAH and AIS has
markedly increased during the past decade in Finland.
This is mainly due to an increased number of patients
requiring neurocritical care being admitted to the ICU,
as mean cost per patient slightly decreased during the
study period. The decrease in mean cost per patient
probably reflects the fact that severity of illness was less
in all diagnostic groups, indicating that more patients
with less severe neurocritical illness are treated in the
ICU nowadays. We also identified major differences in
treatment costs and cost-effectiveness in patients with
TBI, SAH, ICH or AIS. Intensive care of patients with
TBI or SAH resulted more commonly in patients be-
coming independent survivors and was associated with
lower treatment costs compared to ICH and AIS. That
Fig. 3 Left panel, changes in mean costs per patient during the study period (with 95% confidence intervals (CI)]). A trend towards lower mean
costs per patient is noted. Mean cost per patient was €50,162 (95% CI €43,783–€56,541) in 2003 and €38,872 (95% CI €36,236–€41,508) in 2013.
Right panel, changes in the sum of costs (blue bars) and absolute number of patients per year (connected boxes). The sum of costs increased by
76% from 2003 to 2013 (€18.6 million in 2003 and €32.8 million in 2013). The total number of patients increased by 227% from 370 patients in
2003 to 840 patients in 2013
Fig. 4 Effective cost per survivor (ECPS) in blue and effective cost per independent survivor (ECPIS) in red
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said, it should be noted that a direct comparison be-
tween patients with TBI, ICH, SAH or AIS is challenging
due to the varied spectrum of patient demographics,
natural history, ICU admission thresholds, treatment
options and strategies and baseline prognosis.
Comparison with other studies
There are no studies that have comprehensively included
several neurocritical illnesses. Regarding ICH and SAH,
a recent study from Ontario, showed that total direct
and indirect hospital costs for patients with spontaneous
ICH was $53,491 (expressed in Canadian dollars at the
2017 rate, converts to €35,303 at the 2013 rate) and
$92,794 (expressed in Canadian dollars at the 2017 rate,
converts to €61,243 at the 2013 rate) for patients with
SAH [22]. The mean cost per SAH hospital survivor was
$136,097 (expressed in Canadian dollars at the 2017 rate,
converts to €89,797 at the 2013 rate) and the mean cost
per ICH hospital survivor was $94,856 (expressed in
Canadian dollars at the 2017 rate, converts to €62,585 at
the 2013 rate). We found similar results, as the mean
cost per one-year ICH was €84,859 (expressed in euros
at the 2013 rate) and 71,195 (expressed in euros at the
2013 rate), per one-year SAH survivor.
Regarding SAH, a study from the UK in 2001,
showed that the cost per life saved was £40,816
(expressed in pounds sterling at the 2001 rate, con-
verts to €82,546 at the 2013 rate) and the cost to
avoid one bad outcome was £84,366 (expressed in
pounds sterling at the 2001 rate, converts to €170,561
at the 2013 rate) [23]. Quite similarly, the ECPS in
our study was €71,195 (expressed in euros at the
2013 rate) but the ECPIS was markedly lower, being
€96,265 (expressed at the 2013 rate). Another study
from the UK reported that the estimated cost for
treating one patient with SAH was £23,294 (expressed
in pounds sterling at the 2005 rate, converts to
€38,701 at the 2013 rate). This is somewhat lower
than in our study, where the mean cost per patient
with SAH was €51,906 (expressed in euros at the
2013 rate). Yet, the UK study did not include, for
example, medication costs. In our study, the social
security reimbursements were on average €9516 per
patient with SAH, making the results between our
study and the UK study very similar.
SAH was associated with the highest university hos-
pital costs whereas AIS was associated with the lowest
university hospital costs. In contrast to the other diag-
nostic group, most patients with SAH undergo extensive
and costly treatments, including aneurysm clipping or
endovascular treatment [24]. The low university hospital
costs in the AIS group may plausibly be explained by
less severe illness (measured by the APACHE II and
SAPS II), fewer patients being mechanically ventilated,
shorter lengths of stay and lower treatment intensity
(measured by the TISS-76). SAH, on the other hand,
was associated with the highest treatment intensity and
longest length of stay, leading to higher university hos-
pital costs. This and our previous study provide good
data on the cost-effectiveness of intensive care in TBI
[17]. Other TBI studies have identified total one-year
direct and indirect costs between €16,579 and €35,560
(converted to euros at the 2013 rate) [25–27] but data
on cost-effectiveness are lacking.
An inbuilt study bias is that ICU admission criteria vary
among the diagnostic groups included. For example, pa-
tients with SAH are preferably directly admitted to the
ICU in some centers, independent of their level of con-
sciousness, while patients with TBI, ICH or AIS can be
treated outside of the ICU, given an adequate level of con-
sciousness and appropriate radiological findings. Further,
patient age is probably key in ICU selection criteria, as
elderly patients with stroke are often excluded from ag-
gressive ICU treatment. This may distort our results to-
wards improved cost-effectiveness, as some patients are
admitted due to an estimated favorable outcome. It should
also be mentioned that some of the patients included
might be admitted to ICU due to potential organ dona-
tion. The American Heart Association/American Stroke
Association recommends full treatment for at least 2 days
before implementing any treatment limitations [28].
Organ donors often receive aggressive ICU treatment to
uphold adequate organ vitality, which thus, is very
resource-demanding as well. However, assessing the po-
tential ICU treatment cost-effectiveness benefits of organ
donation is out of the scope of this study.
We noted a marked decrease in unadjusted one-year
mortality between 2007 and 2009. During the same years
a substantial increase in patients admitted with ICH or
AIS were noted due to structural changes in some cen-
ters leading to more less severely ill patients being
admitted, which most likely explains the noted shift in
mortality. It should also be highlighted that the vast
majority of patients with ICH or AIS are treated outside
of the ICU setting (for example in stroke units). In our
study setting, only patients with the most severe cases of
ICH and AIS are treated in the ICU, as all hospitals
included have dedicated stroke units. Thus, our study
obviously undervalues the total burden of AIS and ICH
but represent the ICU-treated portion well. Further-
more, during the study period thrombectomy had not
been established in the treatment of large vessel occlu-
sion AIS [29–33]. The patients with and large vessel oc-
clusion AIS probably constitute a notable proportion of
patients with AIS being treated in the ICU prior to the
establishment of thrombectomy. Thus, considering the
effectiveness of thrombectomy for large vessel occlusion,
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the long-term cost-effectiveness of AIS has most likely
improved and the number of patients with AIS requiring
ICU care at all have may have decreased [34, 35]. This
limits the interpretation and the generalization of the
AIS results to the modern thrombectomy era. Cost-ef-
fectiveness correlated strongly with the severity of illness
and the ECPIS was highest among patients with ICH or
AIS in all risk bands, with the exception of risk band 4,
where AIS was associated with the lowest ECPIS. Al-
though we cannot confirm this, it is possible that these
patients represent a group with relatively small infarcts
but severe extracranial organ dysfunction (e.g. respira-
tory dysfunction after basilar artery occlusion), requiring
intensive care, from which recovery is favorable.
Future directions
In our study we noted a steady increase in the number
of neurocritical patients treated in the ICU. This prob-
ably reflects the parallel increase in ICU beds and the
rapidly aging population in Finland, increasing the need
for intensive care [8]. The total number of ICU beds in
Finland is approximately 6 per 100,000 persons, which is
among the lowest in Europe and one fifth of that in the
USA [36, 37]. Thus, considering the rapidly aging popu-
lation a continued increase in the number of patients re-
quiring neurocritical care and an increased demand for
ICU beds are to be expected. Accordingly, efforts should
be put towards preventing these events, as outcomes are
poor and treatment is resource-demanding and costly.
Effectively treating risk factors for stroke (SAH, ICH,
AIS) and TBI has the potential to reduce the burden of
these neurocritical illnesses. For example, the decreased
incidence of smoking in Finland has been linked to a de-
creased incidence in SAH [38]. Similar prevention
should be targeted in TBI, which could be achieved by
avoiding falls among the elderly, and reducing alcohol-
related falls and traffic-related accidents.
Strengths and limitations
This study was conducted in a government tax-funded
healthcare system, where all citizens have the right to
equal care, avoiding selection bias due to differences in
access to treatment. Further, specialized neurointensive
care has for decades been centralized to five university
hospitals and, thus, the current study represents as good
as the whole Finnish adult population. Moreover, data
on rehabilitation hospital length of stay is electronically
recorded on a national level by the Finnish National
Institute for Health and Welfare, making this data
extremely comprehensive. Another unique feature of this
study is that in Finland, social security costs are essen-
tially paid by one institution, Kela, which covers all
Finnish citizens regardless of insurance status. Thus, in
combination with the high-quality FICC database with
the small number of missing patients, our study compre-
hensively catches the burden of neurocritical illnesses
treated in the ICU in a developed country setting [10].
Regarding patients with TBI or SAH, we were able to
include four of five ICUs providing specialized intensive
care for these patients, making the TBI and SAH largely
representative of the whole Finnish population, although
less so than for ICH and AIS. Yet, as already mentioned,
not all patients with AIS or ICH are treated in the ICU.
After the introduction of thrombectomy the number of
patients with AIS requiring ICU care has probably
decreased as well. The noted increase in AIS admissions
in this study is due to a change in local policy in one of
the hospitals leading to more patients with AIS with less
severe illness being treated in the ICU, probably explain-
ing the decrease in unadjusted mortality in the middle of
the study period. Thus, clearly our results on patients
with AIS or ICH cannot be generalized to patients being
treated outside the ICU.
We used a surrogate marker of permanent disability,
i.e. if the patient was granted a permanent disability
allowance or disability pension by Kela. In comparison
to other commonly used outcome scales (e.g. Glasgow
Outcome Scale, modified Rankin Scale), our definition
may include some degree in inaccuracy but considering
that all Finnish citizens are covered by Kela we believe
that our definition adequately reflects neurological out-
come. Further, the FICC database does not contain uni-
formly standardized data on limitation of care from the
beginning of the study period. Thus, some included
patients are probably ICU-treated due to upcoming
potential organ donation.
We did only study adult patients and, thus, our results
cannot directly be generalized to the pediatric popula-
tion. Further, we only included patients with TBI, ICH,
SAH or AIS. Thus, other neurocritical illnesses, such as
cerebral venous thrombosis, status epilepticus, bacterial
meningitis, viral encephalitis and neuromuscular disor-
ders were not included. Last, the study was conducted in
a single Nordic country. Thus, our results are best ap-
plicable to settings with similar healthcare systems.
Conclusion
Neurocritical illnesses are costly and resource-demanding
diseases associated with poor outcomes. The total number
of patients requiring neurocritical care who are admitted to
the ICU has increased leading to an increase in total costs,
although mean cost per patient has remained largely un-
changed. These changes were paralleled with a decrease in
patients’ severity of illness. Intensive care of patients with
TBI or SAH more commonly resulted in them becoming
independent survivors and was associated with lower costs
compared to the care of patients with ICH or AIS.
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Additional files
Additional file 1: The STROBE guidelines. (DOC 84 kb)
Additional file 2: Changes in probability of one-year mortality (with 95%
confidence intervals), reflecting severity of illness, for the diagnostic groups.
The y-axis scale extends from 0 to 0.8, where 0 indicates that the probability
is 0% and 0.8 that the probability is 80%. Probabilities were calculated by lo-
gistic regression analysis adjusting for age, GCS score, chronic comorbidity,
pre-admission functional status and SAPS 2, separately for the diagnostic
groups. A trend towards lower severity of illness was noted in all diagnostic
groups. A small reduction in severity of illness was noted for patients with
traumatic brain injury and subarachnoid hemorrhage. Between 2007 and
2009, severity of illness dropped notably in patients with acute ischemic
stroke and intracerebral hemorrhage. (TIF 323 kb)
Additional file 3: Temporal change in risk bands within the diagnostic
groups. Patients were divided into 4 equally sized risk bands within their
own diagnostic group according to risk of one-year mortality (severity of
illness). The relative proportion of patients in risk bands 1 and 2 increased
with time in all diagnostic groups. The increase was most notable among
patients with ICH and AIS, indicating that more patients with less severe
illness were admitted towards the end of the study period. (TIF 544 kb)
Additional file 4: Changes in the sum of costs and absolute number of
patients during the study period by diagnostic group. The bars (blue)
represent the sum of costs for all patients in the particular diagnostic
group treated during that particular year. The connected boxes indicate
the absolute number of patients in the particular diagnostic group
treated during that particular year. The absolute number of patients
treated in the intensive care unit increased in all diagnostic groups.
Accordingly, the sum of costs increased. (TIF 3003 kb)
Additional file 5: Changes in mean cost per patient (with 95%
confidence intervals) during the study period for the diagnostic groups. A
trend towards lower mean cost per patient was noted in the traumatic
brain injury, intracerebral hemorrhage and acute ischemic stroke groups,
while mean cost per patient remained largely the same for patients in
the subarachnoid hemorrhage group. (TIF 1051 kb)
Additional file 6: Effective cost per survivor (ECPS) and effective cost
per independent survivor (ECPIS) according to diagnostic group and risk
band. Risk band 1 (upper left) represents patients with one-year mortality
risk of 0–25%, risk band 2 (upper right) represents patients with one-year
mortality risk of 26–50%, risk band 3 (lower left) represents patients with
one-year mortality risk of 51–75%, and risk band 4 represent patients with
one-year mortality risk of 76–100%. The risk bands were created
separately for all diagnostic groups by adjusting for age, GCS score, pre-
admission functional status, significant chronic comorbidity and the
modified SAPS II score. (TIF 931 kb)
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